Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 1;43(11):776-780.
doi: 10.1097/DAD.0000000000001909.

Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases

Sherman Chu  1   2 , Kory P Schrom  3 , Raghav Tripathi  1 , Rosalynn R Z Conic  4 , Harib H Ezaldein  1   3 , Jeffrey F Scott  1   3   5 , Kord Honda  1   3
Affiliations

Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases

Sherman Chu et al. Am J Dermatopathol. .

Abstract

Background: Pure and mixed desmoplastic melanomas (DMs) may have different natural histories and behaviors.

Methods: We conducted a retrospective review of patients diagnosed with DM at our institution between January 1997 and April 2019. A total of 33 unique DMs were identified and subsequently analyzed based on the histologic type (pure vs. mixed).

Results: The majority (57.6%) of our cases were classified as pure histology. Patients with pure DMs were more likely to be men (P = 0.035) and be older than 65 years (P = 0.019) compared with patients with mixed DMs. Patients with mixed DM were more likely to have mitoses present (P = 0.001) compared with patients with pure DM. There were no differences in ulceration, perineural invasion, vascular invasion, or survival between patients with pure and mixed histologic subtypes. In addition, no differences in sentinel lymph node biopsy, radiation, or chemotherapy were noted between the 2 histologic subtypes. Immunohistochemistry showed that 27.3% of the pure DMs stained with Melan-A and HMB45 were positive for these immunomarkers.

Conclusions: Pure and mixed variants of DM were found to have similar clinicopathologic characteristics. Patients with the mixed histologic subtype were more likely to have mitoses, but no difference in the therapeutic management or patient survival was seen between the 2 subtypes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
A) Pure desmoplastic melanoma with spindled melanocytes set in a desmoplastic stroma (H&E, 4X magnification). B) Spindled melanocytes set in desmoplastic stroma (H&E, 40X magnification).
Figure 2.
Figure 2.
A) Mixed desmoplastic melanoma with spindled melanocytes set in a fibrotic stroma with a patchy lymphocytic infiltrate that extends into the subcutaneous fat (H&E, 4X magnification) B) Mixed desmoplastic melanoma desmoplastic component with spindle melanocytes with desmoplasia (H&E, 40X magnification). C) Mixed desmoplastic melanoma with more epithelioid and densely packed melanoma cells (H&E, 4X magnification). D) Densely packed more oval melanocytes in the non-desmoplastic portion of this desmoplastic melanoma (H&E, 40X magnification).
See this image and copyright information in PMC

Comment in

References

    1. Pavri SN, Clune J, Ariyan S, Narayan D. Malignant Melanoma: Beyond the Basics. Plast Reconstr Surg. 2016;138(2):330e–340e. - PubMed
    1. Frydenlund N, Mahalingam M. Desmoplastic melanoma, neurotropism, and neurotrophin receptors--what we know and what we do not. Adv Anat Pathol. 2015;22(4):227–241. - PubMed
    1. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol. 2013;68(5):825–833. - PMC - PubMed
    1. Kottschade LA, Grotz TE, Dronca RS, et al. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014;37(6):635–641. - PMC - PubMed
    1. Hadfield MJ, Helsing R, Grant-Kels JM. Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies. Melanoma Res. 2020;30(5):429–432. - PubMed